SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ProKidney Q3 loss widens on higher R&D costs

ProKidney Q3 loss widens on higher R&D costs Overview U.S. cell therapy firm's Q3 net loss widened a

PROK

Related stories